Cargando…
Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6‐week, randomized, double‐blind, placebo‐controlled study
AIM: The aim of this study was to evaluate the efficacy of lurasidone in acute schizophrenia in Japan and other countries. METHODS: Subjects (aged 18–74 years) diagnosed with schizophrenia were randomized to lurasidone 40 mg/day or placebo. The primary efficacy endpoint was change from baseline on t...
Autores principales: | Iyo, Masaomi, Ishigooka, Jun, Nakamura, Masatoshi, Sakaguchi, Reiko, Okamoto, Keisuke, Mao, Yongcai, Tsai, Joyce, Fitzgerald, Alison, Nosaka, Tadashi, Higuchi, Teruhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361730/ https://www.ncbi.nlm.nih.gov/pubmed/33890388 http://dx.doi.org/10.1111/pcn.13221 |
Ejemplares similares
-
Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
por: Iyo, Masaomi, et al.
Publicado: (2021) -
Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study
por: Miura, Itaru, et al.
Publicado: (2022) -
Double‐blind, placebo‐controlled study of lurasidone monotherapy for the treatment of bipolar I depression
por: Kato, Tadafumi, et al.
Publicado: (2020) -
Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
por: Nasrallah, Henry A., et al.
Publicado: (2014) -
Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study
por: Higuchi, Teruhiko, et al.
Publicado: (2021)